Literature DB >> 25296093

Cardiovascular risk assessment in kidney transplantation.

Allyson Hart1, Matthew R Weir2, Bertram L Kasiske1.   

Abstract

Cardiovascular disease (CVD) remains the most common cause of death after kidney transplantation worldwide, with the highest event rate in the early postoperative period. In an attempt to address this issue, screening for CVD prior to transplant is common, but the clinical utility of screening asymptomatic transplant candidates remains unclear. A large degree of variation exists among both transplant center practice patterns and clinical practice guidelines regarding who should be screened, and opinions are based on mixed observational data with great potential for bias. In this review, we discuss the potential risks, benefits, and evidence for screening for CVD in kidney transplant candidates, and also the next steps to better evaluate and treat asymptomatic kidney transplant candidates.

Entities:  

Mesh:

Year:  2014        PMID: 25296093     DOI: 10.1038/ki.2014.335

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  15 in total

1.  Renal transplant complications: Moving toward comparison of relevant parameters and further improvement in outcomes.

Authors:  Ronald B Moore
Journal:  Can Urol Assoc J       Date:  2017-11-01       Impact factor: 1.862

2.  Trends in Coronary Artery Disease Screening before Kidney Transplantation.

Authors:  Xingxing S Cheng; Sai Liu; Jialin Han; Margaret R Stedman; Glenn M Chertow; Jane C Tan; William F Fearon
Journal:  Kidney360       Date:  2021-12-09

Review 3.  Everolimus and sirolimus in transplantation-related but different.

Authors:  Jost Klawitter; Björn Nashan; Uwe Christians
Journal:  Expert Opin Drug Saf       Date:  2015-04-26       Impact factor: 4.250

Review 4.  Role of hypertension in kidney transplant recipients.

Authors:  Charalampos Loutradis; Pantelis Sarafidis; Smaragdi Marinaki; Miriam Berry; Richard Borrows; Adnan Sharif; Charles J Ferro
Journal:  J Hum Hypertens       Date:  2021-05-04       Impact factor: 3.012

5.  Performance versus Risk Factor-Based Approaches to Coronary Artery Disease Screening in Waitlisted Kidney Transplant Candidates.

Authors:  Xingxing S Cheng; Daniel J Watford; Hiroyuki Arashi; Margaret R Stedman; Glenn M Chertow; Jane C Tan; William F Fearon
Journal:  Cardiorenal Med       Date:  2021-05-25       Impact factor: 4.360

6.  Coronary Computed Tomography Angiography in Diagnosing Obstructive Coronary Artery Disease in Patients with Advanced Chronic Kidney Disease: A Systematic Review and Meta-Analysis.

Authors:  Xingxing S Cheng; Suman Mohanty; Valery Turner; Domenico Mastrodicasa; Simon Winther; Dominik Fleischmann; Jane C Tan; William F Fearon
Journal:  Cardiorenal Med       Date:  2020-12-15       Impact factor: 4.360

Review 7.  Older candidates for kidney transplantation: Who to refer and what to expect?

Authors:  Beatrice P Concepcion; Rachel C Forbes; Heidi M Schaefer
Journal:  World J Transplant       Date:  2016-12-24

8.  The Kidney Transplant Evaluation Process in the Elderly: Reasons for Being Turned down and Opportunities to Improve Cost-Effectiveness in a Single Center.

Authors:  Beatrice P Concepcion; Rachel C Forbes; Aihua Bian; Heidi M Schaefer
Journal:  J Transplant       Date:  2016-08-04

9.  Does diabetes impact therapeutic immunomodulation therapy decisions for kidney transplant recipients? Data from the Folic Acid for Vascular Outcome Reduction in Transplant (FAVORIT) trial.

Authors:  Larry A Weinrauch; John A D'Elia; Matthew R Weir; Suphamai Bunnapradist; Peter Finn; Jiankang Liu; Brian Claggett; Anthony P Monaco
Journal:  Int J Nephrol Renovasc Dis       Date:  2017-08-18

Review 10.  The effect of aspirin on kidney allograft outcomes; a short review to current studies.

Authors:  Wisit Cheungpasitporn; Charat Thongprayoon; Donald G Mitema; Michael A Mao; Ankit Sakhuja; Wonngarm Kittanamongkolchai; Maria L Gonzalez-Suarez; Stephen B Erickson
Journal:  J Nephropathol       Date:  2017-01-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.